Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
Violence reduction efforts should be modeled on noncontagious diseases, which have as their root cause environmental determinants, not contagious diseases.
AMA J Ethics. 2018;20(5):513-515. doi:
10.1001/journalofethics.2018.20.5.corr1-1805.
Gary Slutkin, MD, Charles Ransford, MPP, and Daria Zvetina
Violence reduction efforts should focus on interrupting transmission of violence and changing behaviors rather than mitigating environmental risk factors.
AMA J Ethics. 2018;20(5):516-519. doi:
10.1001/journalofethics.2018.20.5.corr2-1805.